TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02043964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tears and cerebrospinal fluid sampling
Description: All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
Study: NCT00959647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib was supplied in capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a solution for intravenous administration.
Study: NCT00538915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Description: Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
Study: NCT00987246

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41005
Description: Topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS106521
Description: Topical
Study: NCT04304768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent
Description: 0.5 ml prefilled syringe administrated intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent
Description: 0.5 ml prefilled syringe administrated intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent
Description: 0.5 ml prefilled syringe administrated intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent
Description: 0.5 ml prefilled syringe administrated intramuscularly
Study: NCT02802306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Description: Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
Study: NCT01432171

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT01618799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Tablets 25 mg
Description: 2 x 25 mg tablet once a day
Study: NCT00669994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Cipro XR 500 mg tablets taken once daily
Study: NCT00626678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
Study: NCT03939143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01(A), Sugamet SR Tab 5/1000mg®
Description: Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)
Description: Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.
Study: NCT00456846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: 100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
Study: NCT04922086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional aesthetic crown lengthening surgery
Description: The demarcation of the gingival zenith final position will be done on the teeth using a periodontal probe. This demarcation will be done through visual examination based on the crown length/width ratio and the position of the cemento-enamel junction (CEJ). The gingival margin of the central and canine incisors will be positioned at similar heights and a more coronal gingival contour will be determined for the lateral incisors. An internal bevel incision will be made with a blade on each tooth, preserving the interdental papillae. The incised gingival tissue will be removed using a periodontal curette in both groups. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). Carbide drills and manual chisels will be used for bone resection to obtained a CEJ-BC distance of 3 mm. Simple interproximal interrupted sutures will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided dual aesthetic crown lengthening surgery
Description: The double guide will be positioned and an internal bevel incision on each tooth will be made following the guide demarcation. After the initial incision, the incised gingival tissue will be removed using a periodontal curette. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). The dual guide will be positioned again and the bone tissue will be removed using carbide drills and manual chisels following the double guide. No interproximal crestal bone will be removed. Simple interproximal interrupted sutures will be performed to stabilize the flap.
Study: NCT00626678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
Study: NCT00421044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone/EPO906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone/EPO906
Study: NCT01684917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metabolomic and Energy Intake Restriction
Description: Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Metabolomic and Energy Intake Restriction
Description: Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metabolomic and Energy Intake Restriction
Description: Metabolomic inquiry followed by a 12 week energy intake restriction. This study is part of a very large European study called EPIC. Only the results by Lee et al. 2016 have been presented here. The results of the study published by Cheung 2017 are from a different study. therefore the entries for the results are correct. For this particular study, participants were not randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option. In summary, both studies (lee and cheung) are considered as separate trials and results of the first phase where participants were assigned to one of five different diets, are reported separately. Unfortunately no different NCT number is available.
Study: NCT01001221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~* Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1
Study: NCT00421044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone/EPO906
Study: NCT02299154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological questionnaires
Description: Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological questionnaires
Description: Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
Study: NCT02383056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnilux
Description: Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Omnilux Sham
Description: Sham light instead of phototherapy from the same light device
Study: NCT01001221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~* Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule~* Study part 2: MTD as determined in Study part 1.
Study: NCT04460885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks
Study: NCT04257357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-weeks supervised exercise program
Description: Please refer to group description
Study: NCT00005829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT00978796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
Study: NCT04257357

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Please refer to group description
Study: NCT03566290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.
Study: NCT00978796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
Study: NCT01813929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
Study: NCT00007345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Study: NCT05747053

Intervention type: DIAGNOSTIC_TEST
Intervention: AlloSure
Description: AlloSure blood-draw at Post-operation day one and four, as well as one month, 2 months, 3, 9, 12, 15,18 and 24 months operation.
Study: NCT03724136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Bone Marrow Stem Cell (BMSC) Fraction
Description: 14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Bone Marrow Stem Cell (BMSC) Fraction
Description: 14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Bone Marrow Stem Cell (BMSC) Fraction
Description: 14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction
Description: Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near Infrared Light
Description: Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
Study: NCT05747053

Intervention type: DIAGNOSTIC_TEST
Intervention: PAXGene
Description: 1 PAXgene tube will be collected with every biopsy performed and sent with the AlloSure test for the second 100 patients (patients 101-200). 21 gene markers will be sequenced by collecting 3 ml of blood.
Study: NCT05249439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I-SatPro weight loss programme
Description: I-SatPro weight loss programme: patients asked to make changes to food choices, the timing of eating, exercise, sleep, eating habits and behaviour changes related to self-care and wellbeing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-SatPro weight loss programme
Description: I-SatPro weight loss programme: patients asked to make changes to food choices, the timing of eating, exercise, sleep, eating habits and behaviour changes related to self-care and wellbeing
Study: NCT01776541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine
Study: NCT01694173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem cell therapy- SPD artery
Description: A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell therapy- splenic artery
Description: 7 patients will receive stem cells infusion through splenic artery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell therapy-intravenous
Description: 7 patients will receive stem cells infusion through peripheral intravenous route.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo -sham procedure
Description: 7 patients will receive infusion of normal saline and will act as control groups
Study: NCT00618618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00087152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000 mg/m\^2 by mouth twice daily Days 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 400 mg by mouth daily
Study: NCT05321901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychosocial Exercise Therapy approach (BETY)
Description: The BETY intervention is grouped under 4 headings: Patient education on chronic pain, functional body stabilization exercises (mind-body information management), dance therapy-authentic movement (emotion-state information management), and sexual information management.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group participants were those who did not want to receive exercise treatment with telerehabilitation and took their routine medications during the 8 weeks period.
Study: NCT04662021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Participants perform one hour of regular moderate to vigorous physical activities about (70 % to 90 %) of the maximum heart rate which was calculated according to this formula (HR max= 220- age)
Study: NCT00618618

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04410523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSJ117
Description: CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment
Study: NCT01735422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: u-hCG
Description: Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter \>= 18 mm, not more than 5 follicles with diameter \>= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
Study: NCT04238910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximizing Energy
Description: The intent of the MAX intervention is to personalize OT delivered education to facilitate the implementation of Energy Conservation strategies using the PST framework to address specific fatigue-related problems and then to generalize from these solutions to both similar and new situations in daily life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: The intent of the health education intervention is to control for the non-specific effects of interactions with an interventionist. Participants received education on a variety of health related topics relevant to individuals with TBI.
Study: NCT04592939

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate weight bearing after surgery
Description: immediate weight bearing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 6 weeks of toe-touch weight bearing after surgery
Description: 6 weeks of toe-touch weight bearing
Study: NCT03199976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: Tiotropium Bromide 2.5 µg/dose inhaled aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate 125 µg/dose inhaled aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol 0.1 mg/dose inhaled aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol 0.1 mg/dose inhaled aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol 0.1 mg/dose inhaled aerosol
Study: NCT03868514

Intervention type: DEVICE
Intervention: TiLOOP® Bra Pocket
Description: Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket